tbuckley/cabot-search huggingface dataset:
Errors in the Byline and Text
Authors: Atsuyuki Watanabe, Jun Yasuhara, Toshiki Kuno
Journal: JAMA Pediatrics (2023)

be very challenging to conduct large-scale randomized trials, given the ample evidence supporting the benefit of COVID-19 vaccination.Finally, our article could not extensively assess the most effective timing and dose of vaccination since only a few studies reported the difference in the maternal or neonatal protective effects among the first, second, and third trimesters.In our original article, 1 vaccination during the second or third trimester was associated with lower incidences of preterm birth and small for gestational age.However, it was compared with unvaccinated individuals instead of those vaccinated during the first trimester.Therefore, it is difficult to determine the best time to receive vaccinations to protect children.Nevertheless, even if it were proven that getting vaccinated later in pregnancy compared with earlier was more effective in reducing neonatal outcomes, that would not necessarily dictate the best timing to be vaccinated because unvaccinated individuals would have to remain having higher risks of SARS-CoV-2 infection while waiting for the second or third trimester.Under current consensus, it can be recommended that pregnant individuals or those of reproductive age be vaccinated against COVID-19.Overall, we agree that our meta-analysis has several limitations to be acknowledged.However, our findings would promote vaccinating pregnant individuals who have not received one yet due to concerns for the safety and efficacy of COVID-19 vaccines.Future investigations on the optimal dose and timing of COVID-19 vaccination, including the ones for the Omicron subvariant, for pregnant individuals, are warranted.
Benefits and Risks of Periconceptional Folic Acid Supplementation—Reply
Authors: Håkon Magne Vegrim, Torbjörn Tomson, Marte-Helene Bjørk
Journal: JAMA Neurology (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Detection of gut and mucosal peptides through <scp>TOMAHAQ</scp> in healthy individuals
Authors: E. S. Parsons, F. Liu, A. Kaushik, A. Lee, J. Schuetz, D. Dunham, H. Seastedt, I. Ogulur, A. Heider, G. Tan, A. Shah, S. Cao, E. Smith, L. Kost, S. Acharya, M. Prunicki, M. Rothenberg, S. Sindher, R. Leib, C. A. Akdis, K. Nadeau, S. Lejeune
Journal: Allergy (2023)

Appendix S1: Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Error in Methods Section
Authors: Håkon Vegrim, Torbjörn Tomson, Marte-Helene Bjørk
Journal: JAMA Neurology (2023)

Deborah A. Levine, MD, MPH; Alden L. Gross, PhD; Emily M. Briceño, PhD; Nicholas Tilton, PhD; Mohammed U. Kabeto, MS; Stephanie M. Hingtgen, MPP; Bruno J. Giordani, PhD; Jeremy B. Sussman, MD, MS; Rodney A. Hayward, MD; James F. Burke, MD, MS; Mitchell S. V. Elkind, MD, MS; Jennifer J. Manly, PhD; Andrew E. Moran, MD, MPH; Erin R. Kulick, PhD; Rebecca F. Gottesman, MD, PhD; Keenan A. Walker, PhD; Yuichiro Yano, MD, PhD; Darrell J. Gaskin, PhD; Stephen Sidney, MD, MPH; Kristine Yaffe, MD; Ralph L. Sacco, MD, MS; Clinton B. Wright, MD, MS; Veronique L. Roger, MD, MPH; Norrina Bai Allen, PhD; Andrzej T. Galecki, MD, PhD
Limb to Cranial Overflow Dystonia in a Patient After Stroke
Authors: Arka Prava Chakraborty, Adreesh Mukherjee, Atanu Biswas
Journal: JAMA Neurology (2023)

This case report describes noncontiguous overflow dystonia in a patient with diabetes, hypertension, and a history of left putaminal hemorrhage and right hemiparesis.
Error in Author Affiliations
Authors: Atsuyuki Watanabe, Jun Yasuhara, Toshiki Kuno
Journal: JAMA Pediatrics (2023)

be very challenging to conduct large-scale randomized trials, given the ample evidence supporting the benefit of COVID-19 vaccination.Finally, our article could not extensively assess the most effective timing and dose of vaccination since only a few studies reported the difference in the maternal or neonatal protective effects among the first, second, and third trimesters.In our original article, 1 vaccination during the second or third trimester was associated with lower incidences of preterm birth and small for gestational age.However, it was compared with unvaccinated individuals instead of those vaccinated during the first trimester.Therefore, it is difficult to determine the best time to receive vaccinations to protect children.Nevertheless, even if it were proven that getting vaccinated later in pregnancy compared with earlier was more effective in reducing neonatal outcomes, that would not necessarily dictate the best timing to be vaccinated because unvaccinated individuals would have to remain having higher risks of SARS-CoV-2 infection while waiting for the second or third trimester.Under current consensus, it can be recommended that pregnant individuals or those of reproductive age be vaccinated against COVID-19.Overall, we agree that our meta-analysis has several limitations to be acknowledged.However, our findings would promote vaccinating pregnant individuals who have not received one yet due to concerns for the safety and efficacy of COVID-19 vaccines.Future investigations on the optimal dose and timing of COVID-19 vaccination, including the ones for the Omicron subvariant, for pregnant individuals, are warranted.
Understanding Diversity in Life Course Social Determinants of Dementia Risk and Resilience in the Asian American Older Adult Population
Authors: Sarah E. Tom
Journal: JAMA Network Open (2023)

Eleanor Hayes-Larson, PhD, MPH; Ryo Ikesu, MD; Joseph Fong, MPH; Taylor M. Mobley, MPH; Gilbert C. Gee, PhD; Ron Brookmeyer, PhD; Rachel A. Whitmer, PhD; Paola Gilsanz, PhD; Elizabeth Rose Mayeda, PhD, MPH
LSD1 Inhibition Disrupts Super-Enhancer–Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer
Authors: Muqing Li, Mingyu Liu, Wanting Han, Zifeng Wang, Dong Han, Susan Patalano, Jill A. Macoska, Steven P. Balk, Housheng Hansen He, Eva Corey, Shuai Gao, Changmeng Cai
Journal: Cancer Research (2023)

The lysine demethylase LSD1 (also called KDM1A) plays important roles in promoting multiple malignancies including both hematologic cancers and solid tumors. LSD1 targets histone and nonhistone proteins and can function as a transcriptional corepressor or coactivator. LSD1 has been reported to act as a coactivator of androgen receptor (AR) in prostate cancer and to regulate the AR cistrome via demethylation of its pioneer factor FOXA1. A deeper understanding of the key oncogenic programs targeted by LSD1 could help stratify prostate cancer patients for treatment with LSD1 inhibitors, which are currently under clinical investigation. In this study, we performed transcriptomic profiling in an array of castration-resistant prostate cancer (CRPC) xenograft models that are sensitive to LSD1 inhibitor treatment. Impaired tumor growth by LSD1 inhibition was attributed to significantly decreased MYC signaling, and MYC was found to be a consistent target of LSD1. Moreover, LSD1 formed a network with BRD4 and FOXA1 and was enriched at super-enhancer regions exhibiting liquid-liquid phase separation. Combining LSD1 inhibitors with BET inhibitors exhibited strong synergy in disrupting the activities of multiple drivers in CRPC, thereby inducing significant growth repression of tumors. Importantly, the combination treatment showed superior effects than either inhibitor alone in disrupting a subset of newly identified CRPC-specific super-enhancers. These results provide mechanistic and therapeutic insights for cotargeting two key epigenetic factors and could be rapidly translated in the clinic for CRPC patients.LSD1 drives prostate cancer progression by activating super-enhancer-mediated oncogenic programs, which can be targeted with the combination of LSD1 and BRD4 inhibitors to suppress the growth of CRPC.
Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non–ST-Segment Elevation Acute Myocardial Infarction
Authors: Juan Sanchis, Héctor Bueno, Gema Miñana, Carme Guerrero, David Martí, Manuel Martínez-Sellés, Laura Domínguez-Pérez, Pablo Díez-Villanueva, Jose A. Barrabés, Francisco Marín, Adolfo Villa, Marcelo Sanmartín, Cinta Llibre, Alessandro Sionís, Antoni Carol, Sergio García-Blas, Elena Calvo, María José Morales Gallardo, Jaime Elízaga, Iván Gómez-Blázquez, Fernando Alfonso, Bruno García del Blanco, Julio Núñez, Francesc Formiga, Albert Ariza-Solé
Journal: JAMA Internal Medicine (2023)

To our knowledge, no randomized clinical trial has compared the invasive and conservative strategies in frail, older patients with non-ST-segment elevation acute myocardial infarction (NSTEMI).
Error in Text
Authors: Atsuyuki Watanabe, Jun Yasuhara, Toshiki Kuno
Journal: JAMA Pediatrics (2023)

Daniel M. Bagner, PhD, ABPP; Michelle D. Berkovits, PhD; Stefany Coxe, PhD; Natalie Frech, BA; Dainelys Garcia, PhD; Alexandra Golik, MA; Brynna H. Heflin, MS; Perrine Heymann, MS; Natalie Javadi, PhD; Amanda L. Sanchez, PhD; Maria K. Wilson, BA; Jonathan S. Comer, PhD
Error in Methods
Journal: JAMA Network Open (2023)

Deborah A. Levine, MD, MPH; Alden L. Gross, PhD; Emily M. Briceño, PhD; Nicholas Tilton, PhD; Bruno J. Giordani, PhD; Jeremy B. Sussman, MD, MS; Rodney A. Hayward, MD; James F. Burke, MD, MS; Stephanie Hingtgen, MPP; Mitchell S. V. Elkind, MD, MS; Jennifer J. Manly, PhD; Rebecca F. Gottesman, MD, PhD; Darrell J. Gaskin, PhD; Stephen Sidney, MD, MPH; Ralph L. Sacco, MD, MS; Sarah E. Tom, PhD, MPH; Clinton B. Wright, MD, MS; Kristine Yaffe, MD; Andrzej T. Galecki, MD, PhD
Diagnostic Yield of Exome Sequencing in Cerebral Palsy and Implications for Genetic Testing Guidelines
Authors: Pedro J. Gonzalez-Mantilla, Yirui Hu, Scott M. Myers, Brenda M. Finucane, David H. Ledbetter, Christa L. Martin, Andres Moreno-De-Luca
Journal: JAMA Pediatrics (2023)

Importance Exome sequencing is a first-tier diagnostic test for individuals with neurodevelopmental disorders, including intellectual disability/developmental delay and autism spectrum disorder; however, this recommendation does not include cerebral palsy. Objective To evaluate if the diagnostic yield of exome or genome sequencing in cerebral palsy is similar to that of other neurodevelopmental disorders. Data Sources The study team searched PubMed for studies published between 2013 and 2022 using cerebral palsy and genetic testing terms. Data were analyzed during March 2022. Study Selection Studies performing exome or genome sequencing in at least 10 participants with cerebral palsy were included. Studies with fewer than 10 individuals and studies reporting variants detected by other genetic tests were excluded. Consensus review was performed. The initial search identified 148 studies, of which 13 met inclusion criteria. Data Extraction and Synthesis Data were extracted by 2 investigators and pooled using a random-effects meta-analysis. Incidence rates with corresponding 95% CIs and prediction intervals were calculated. Publication bias was evaluated by the Egger test. Variability between included studies was assessed via heterogeneity tests using the I 2 statistic. Main Outcomes and Measures The primary outcome was the pooled diagnostic yield (rate of pathogenic/likely pathogenic variants) across studies. Subgroup analyses were performed based on population age and on the use of exclusion criteria for patient selection. Results Thirteen studies were included consisting of 2612 individuals with cerebral palsy. The overall diagnostic yield was 31.1% (95% CI, 24.2%-38.6%; I 2 = 91%). The yield was higher in pediatric populations (34.8%; 95% CI, 28.3%-41.5%) than adult populations (26.9%; 95% CI, 1.2%-68.8%) and higher among studies that used exclusion criteria for patient selection (42.1%; 95% CI, 36.0%-48.2%) than those that did not (20.7%; 95% CI, 12.3%-30.5%). Conclusions and Relevance In this systematic review and meta-analysis, the genetic diagnostic yield in cerebral palsy was similar to that of other neurodevelopmental disorders for which exome sequencing is recommended as standard of care. Data from this meta-analysis provide evidence to support the inclusion of cerebral palsy in the current recommendation of exome sequencing in the diagnostic evaluation of individuals with neurodevelopmental disorders.
Cecum axis (CecAx) preservation reveals physiological and pathological gradients in mouse gastrointestinal epithelium
Authors: Hannah M. Lunnemann, Nicolas G. Shealy, Michelle L. Reyzer, John A. Shupe, Emily H. Green, Uswah Siddiqi, D. Borden Lacy, Mariana X. Byndloss, Nicholas O. Markham
Journal: Gut Microbes (2023)

The mouse cecum has emerged as a model system for studying microbe-host interactions, immunoregulatory functions of the microbiome, and metabolic contributions of gut bacteria. Too often, the cecum is falsely considered as a uniform organ with an evenly distributed epithelium. We developed the cecum axis (CecAx) preservation method to show gradients in epithelial tissue architecture and cell types along the cecal ampulla-apex and mesentery-antimesentery axes. We used imaging mass spectrometry of metabolites and lipids to suggest functional differences along these axes. Using a model of
International Consensus Statement on the Radiological Screening of Contact Children in the Context of Suspected Child Physical Abuse
Authors: Kshitij Mankad, Jai Sidpra, David M. Mirsky, Adam J. Oates, Gabrielle C. Colleran, Leandro T. Lucato, Elaine Kan, Tracy Kilborn, Nina Agrawal, Arianne H. Teeuw, Patrick Kelly, Deborah Zeitlin, Jamieson Carter, Geoff D. Debelle, Rachel P. Berger, Cindy W. Christian, Daniel M. Lindberg, Maria Raissaki, Maria Argyropoulou, Catherine Adamsbaum, Timothy Cain, Rick R. van Rijn, V. Michelle Silvera, Andrea Rossi, Alison M. Kemp, Arabinda K. Choudhary, Amaka C. Offiah
Journal: JAMA Pediatrics (2023)

Importance Physical abuse is a common but preventable cause of long-term childhood morbidity and mortality. Despite the strong association between abuse in an index child and abuse in contact children, there is no guidance outlining how to screen the latter, significantly more vulnerable group, for abusive injuries. Consequently, the radiological assessment of contact children is often omitted, or variably performed, allowing occult injuries to go undetected and increasing the risk of further abuse. Objective To report an evidence-based and consensus-derived set of best practices for the radiological screening of contact children in the context of suspected child physical abuse. Evidence Review This consensus statement is supported by a systematic review of the literature and the clinical opinion of an internationally recognized group of 26 experts. The modified Delphi consensus process comprised 3 meetings of the International Consensus Group on Contact Screening in Suspected Child Physical Abuse held between February and June 2021. Findings Contacts are defined as the asymptomatic siblings, cohabiting children, or children under the same care as an index child with suspected child physical abuse. All contact children should undergo a thorough physical examination and a history elicited prior to imaging. Contact children younger than 12 months should have neuroimaging, the preferred modality for which is magnetic resonance imaging, and skeletal survey. Contact children aged 12 to 24 months should undergo skeletal survey. No routine imaging is indicated in asymptomatic children older than 24 months. Follow-up skeletal survey with limited views should be performed if abnormal or equivocal at presentation. Contacts with positive findings should be investigated as an index child. Conclusions and Relevance This Special Communication reports consensus recommendations for the radiological screening of contact children in the context of suspected child physical abuse, establishing a recognized baseline for the stringent evaluation of these at-risk children and providing clinicians with a more resilient platform from which to advocate for them.
Destabilization of Atherosclerotic Plaque by Bilirubin Deficiency
Authors: Weiyu Chen, Sergey Tumanov, Christopher P. Stanley, Stephanie M.Y. Kong, James Nadel, Niv Vigder, Darren L. Newington, Xiao Suo Wang, Louise L. Dunn, Roland Stocker
Journal: Circulation Research (2023)

The rupture of atherosclerotic plaque contributes significantly to cardiovascular disease. Plasma concentrations of bilirubin-a byproduct of heme catabolism-inversely associate with risk of cardiovascular disease, although the link between bilirubin and atherosclerosis remains unclear.To assess the role of bilirubin in atherosclerotic plaque stability, we crossed Bvra-/- with Apoe-/- mice and used the tandem stenosis model of plaque instability. Human coronary arteries were obtained from heart transplant recipients. Analysis of bile pigments, heme metabolism, and proteomics were performed by liquid chromatography tandem mass spectrometry. MPO (myeloperoxidase) activity was determined by in vivo molecular magnetic resonance imaging, liquid chromatography tandem mass spectrometry analysis, and immunohistochemical determination of chlorotyrosine. Systemic oxidative stress was evaluated by plasma concentrations of lipid hydroperoxides and the redox status of circulating Prx2 (peroxiredoxin 2), whereas arterial function was assessed by wire myography. Atherosclerosis and arterial remodeling were quantified by morphometry and plaque stability by fibrous cap thickness, lipid accumulation, infiltration of inflammatory cells, and the presence of intraplaque hemorrhage.Compared with Bvra+/+Apoe-/- tandem stenosis littermates, Bvra-/-Apoe-/- tandem stenosis mice were deficient in bilirubin, showed signs of increased systemic oxidative stress, endothelial dysfunction, as well as hyperlipidemia, and had a higher atherosclerotic plaque burden. Heme metabolism was increased in unstable compared with stable plaque of both Bvra+/+Apoe-/- and Bvra-/-Apoe-/- tandem stenosis mice and in human coronary plaques. In mice, Bvra deletion selectively destabilized unstable plaque, characterized by positive arterial remodeling and increased cap thinning, intraplaque hemorrhage, infiltration of neutrophils, and MPO activity. Proteomic analysis confirmed Bvra deletion enhanced extracellular matrix degradation, recruitment and activation of neutrophils, and associated oxidative stress in unstable plaque.Bilirubin deficiency, resulting from global Bvra deletion, generates a proatherogenic phenotype and selectively enhances neutrophil-mediated inflammation and destabilization of unstable plaque, thereby providing a link between bilirubin and cardiovascular disease risk.
Evaluation of Risk of Bias in Neuroimaging-Based Artificial Intelligence Models for Psychiatric Diagnosis
Authors: Zhiyi Chen, Xuerong Liu, Qingwu Yang, Yan-Jiang Wang, Kuan Miao, Zheng Gong, Yang Yu, Artemiy Leonov, Chunlei Liu, Zhengzhi Feng, Hu Chuan-Peng
Journal: JAMA Network Open (2023)

Importance Neuroimaging-based artificial intelligence (AI) diagnostic models have proliferated in psychiatry. However, their clinical applicability and reporting quality (ie, feasibility) for clinical practice have not been systematically evaluated. Objective To systematically assess the risk of bias (ROB) and reporting quality of neuroimaging-based AI models for psychiatric diagnosis. Evidence Review PubMed was searched for peer-reviewed, full-length articles published between January 1, 1990, and March 16, 2022. Studies aimed at developing or validating neuroimaging-based AI models for clinical diagnosis of psychiatric disorders were included. Reference lists were further searched for suitable original studies. Data extraction followed the CHARMS (Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies) and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines. A closed-loop cross-sequential design was used for quality control. The PROBAST (Prediction Model Risk of Bias Assessment Tool) and modified CLEAR (Checklist for Evaluation of Image-Based Artificial Intelligence Reports) benchmarks were used to systematically evaluate ROB and reporting quality. Findings A total of 517 studies presenting 555 AI models were included and evaluated. Of these models, 461 (83.1%; 95% CI, 80.0%-86.2%) were rated as having a high overall ROB based on the PROBAST. The ROB was particular high in the analysis domain, including inadequate sample size (398 of 555 models [71.7%; 95% CI, 68.0%-75.6%]), poor model performance examination (with 100% of models lacking calibration examination), and lack of handling data complexity (550 of 555 models [99.1%; 95% CI, 98.3%-99.9%]). None of the AI models was perceived to be applicable to clinical practices. Overall reporting completeness (ie, number of reported items/number of total items) for the AI models was 61.2% (95% CI, 60.6%-61.8%), and the completeness was poorest for the technical assessment domain with 39.9% (95% CI, 38.8%-41.1%). Conclusions and Relevance This systematic review found that the clinical applicability and feasibility of neuroimaging-based AI models for psychiatric diagnosis were challenged by a high ROB and poor reporting quality. Particularly in the analysis domain, ROB in AI diagnostic models should be addressed before clinical application.
Prevalence of Diabetes and Cardiovascular Risk in the Middle East and Africa: Primary Results of the PACT-MEA Study
Authors: Subodh Verma, Naji Alamuddin, Fatheya Alawadi, Hessa Alkandari, Wael Almahmeed, Samir H. Assaad-Khalil, Jihad Haddad, Lise Lotte N. Husemoen, Landman Lombard, Rayaz A. Malik, Emel Mashaki Ceyhan, Hani Sabbour, Gamze Tombak, Gourav Yadav, Sam Salek
Journal: Circulation (2023)
Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial
Authors: Eliézer K N'Goran, Maurice R Odiere, Ronald Assandé Aka, Mamadou Ouattara, N A David Aka, Bernhards Ogutu, Fredrick Rawago, Wilhelmina M Bagchus, Matthias Bödding, Elly Kourany-Lefoll, Aliona Tappert, Xiaoyan Yin, Deon Bezuidenhout, Henk Badenhorst, Eric Huber, Benjamin Dälken, Okba Haj-Ali Saflo
Journal: The Lancet Infectious Diseases (2023)
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial
Authors: Keiju Aokage, Kenji Suzuki, Hisashi Saji, Masashi Wakabayashi, Tomoko Kataoka, Yuta Sekino, Haruhiko Fukuda, Makoto Endo, Aritoshi Hattori, Takahiro Mimae, Tomohiro Miyoshi, Mitsuhiro Isaka, Hiroshige Yoshioka, Ryu Nakajima, Kazuo Nakagawa, Jiro Okami, Hiroyuki Ito, Hiroaki Kuroda, Masahiro Tsuboi, Norihito Okumura, Makoto Takahama, Yasuhisa Ohde, Tadashi Aoki, Yasuhiro Tsutani, Morihito Okada, Shun-Ichi Watanabe
Journal: The Lancet Respiratory Medicine (2023)